Mitochondrial permeability transition pore complex (mPTP)

The Mitochondrial Permeability Transition Pore (mPTP) is a high-conductance, non-selective protein complex located in the inner mitochondrial membrane that opens in response to stressors such as calcium overload, oxidative stress, and adenine nucleotide depletion (PMID: 28214301). Its opening causes a sudden increase in membrane permeability, leading to the dissipation of the proton motive force, matrix swelling, and the eventual rupture of the outer mitochondrial membrane, which releases pro-apoptotic factors like cytochrome c into the cytosol (PMID: 30611616). While its exact molecular composition is still debated, it is functionally regulated by Cyclophilin D (CypD) and involves components like the Adenine Nucleotide Translocase (ANT) and potentially the F-ATP synthase (UniProt: P30405). The mPTP is a critical mediator of cell death in various pathologies, including myocardial infarction, stroke, and neurodegenerative disorders such as Alzheimer's and Parkinson's disease (PMID: 25262140). Therapeutic strategies focus on inhibiting mPTP opening to protect tissues from acute and chronic damage, with Cyclosporine A and its non-immunosuppressive derivatives, such as Alisporivir, being the most prominent pharmacological agents (PMID: 21903030).

Other names

Mitochondrial permeability transition poremPTPMPTPMitochondrial megachannelPTP complex

The primary mechanism involves the inhibition of Cyclophilin D (CypD), a key regulatory protein that sensitizes the pore to calcium-induced opening. By binding to CypD, inhibitors like Cyclosporine A prevent its interaction with the inner mitochondrial membrane, thereby increasing the calcium threshold required for pore formation and preventing mitochondrial depolarization (PMID: 17692810, 28214301).